Pfizer's Obesity Drug Candidate Faces Safety Concerns, Causing Stock Drop
Pfizer's Obesity Drug Candid...
Subscribe to Newsletter

Pfizer's Obesity Drug Candidate Faces Safety Concerns, Causing Stock Drop

26 June 2023
3569
2 min.
6
Pfizer's Obesity Drug Candidate Faces Safety Concerns, Causing Stock Drop

Pfizer's Weight Loss Drug Halted

Pfizer Inc. shares fell after halting the development of an oral weight loss drug due to safety concerns, causing investor worry about a competing therapy. The decision was based on elevated levels of liver enzymes found in mid-stage studies, although no patients reported liver side effects.

First Development and Market Analysis

Pfizer's shares dropped 5.6% in New York, their biggest decline since Feb 2022. Struggling to recover from waning Covid vaccine demand, Pfizer aims to catch up with Novo Nordisk and Eli Lilly in the $100B+ obesity-treatment market. Their hopes lie with danuglipron, a new treatment in development, set to compete with Novo's Wegovy and Lilly's Mounjaro.

Concerns About Competitiveness

Lilly and Novo are working on oral obesity drugs, offering a convenient alternative to injections. Analysts worry about danuglipron's twice-daily dosage affecting its competitiveness. Bloomberg Intelligence experts question Pfizer's optimistic $10 billion sales estimate for danuglipron, citing challenges with the pill's frequency.

Comparison with Competing Drugs

Lotiglipron, the discontinued drug by Pfizer, offered convenient once-daily oral treatment. Pfizer's choice to discontinue it was influenced by the emergence of favorable data regarding a competing experimental treatment from Lilly called orforglipron, which follows the same once-daily administration. On the other hand, Pfizer is currently conducting mid-stage studies on their twice-daily version of danuglipron, with no reported cases of elevated liver enzymes among the 1,400+ patients participating in the trials.

William Sessa, Pfizer's SVP and Chief Scientific Officer for Internal Medicine Research, announced the development of two treatments, aiming to choose one for further progress. Pfizer plans to finalize late-stage development plans for danuglipron by end-2023 and is also working on a modified release version for daily use.

Timeframe and Comparison to Competitor

According to JPMorgan analysts led by Chris Schott, Pfizer's once-a-day version of danuglipron is expected to require additional development time, while Lilly has progressed its daily drug to late-stage trials. This analysis suggests a potential disadvantage for Pfizer's drug in terms of market readiness and competition.

Persons1 and Companies5 in the news

Director of the Vascular Biology & Therapeutics Program at Yale School of Medicine
1 place
Novo Nordisk
1 place
Pfizer
3 place
JP Morgan Chase
4 place
Bloomberg L.P.
5 place
Section:
Rating companies
Instagram
15 Mention
Tesla
14 Mention
Netflix
14 Mention
JP Morgan Chase
11 Mention
Amazon
10 Mention
Ford Motor Company
10 Mention
TikTok
8 Mention
White House
7 Mention

NEW YORK NEWS

News from GlobalNY.biz is the freshest and most relevant information about high-profile events in the region. The task of the resource's news feed is to convey to readers with maximum accuracy and objectivity information about important events in business, politics, economy, healthcare, culture and other spheres of life in New York.
GlobalNY.biz news is a coverage of economic processes taking place in New York, the latest news of public life, incidents and an overview of political events. New York news is information about the activities of small and medium-sized businesses, the work of housing and communal services and utilities, the implementation of significant projects.
The site's journalists describe not only the life of the region, but also talk about the current state of the US economy. Everything you need to know about innovations in the field of industry and agriculture, economy and power is collected in the "News" section at GlobalNY.biz.
New York news quickly informs the reader, shows the real picture and opens up hot topics. Communication with government structures and business enables us to provide our readers with reliable, information-rich material. The main page of the portal contains the key news of New York!
Alena Potapova

Development Director
Population
8132802778
Died this year
28066940
Born this year
69049640